Quinone derivatives, their production and use
    4.
    发明授权
    Quinone derivatives, their production and use 失效
    喹诺酮衍生物,其生产和使用

    公开(公告)号:US5304658A

    公开(公告)日:1994-04-19

    申请号:US923598

    申请日:1992-08-03

    CPC classification number: A61C15/02

    Abstract: Quinone derivatives of the general formula: ##STR1## (wherein R.sup.1 and R.sup.2 are the same or different, and independently are a hydrogen atom or a methyl or methoxy group, or R.sup.1 and R.sup.2 combine with each other to represent --CH.dbd.CH--CH.dbd.CH--; R.sup.3 is a hydrogen atom or a methyl group; R.sup.4 is an aliphatic, aromatic or heterocyclic group which may be substituted; R.sup.5 is a methyl or methoxy group, a hydroxymethyl group which may be substituted or a carboxyl group which may be esterified or amidated; Z is a group represented by --C.tbd.C--, --CH.dbd.CH--, ##STR2## n is an integer of 0 to 10; m is an integer of 0 to 3; k is an integer of 0 to 5, provided, however, that in the case of m being 2 or 3, Z and k can vary arbitrarily within the bracketed repeating units) are novel compounds, possess metabolism ameliorating action for polyunsaturate fatty acids, particularly production inhibitory activity of lipid peroxides (antioxidant activity), thromboxane A.sub.2 receptor antagonism, or production inhibitory activity of 5-lipoxygenase metabolites in mammals, and of use as drugs, such as antiasthmatic, antiallergic agent and cerebral-circulatory metabolism ameliorating agent.

    Abstract translation: 喹啉酮衍生物,其通式为:其中R 1和R 2相同或不同,独立地为氢原子或甲基或甲氧基,或者R 1和R 2彼此结合,表示-CH = CH-CH = CH-; R3为氢原子或甲基; R4为可被取代的脂肪族,芳香族或杂环基; R5为甲基或甲氧基,可被取代的羟甲基或羧基 其可以被酯化或酰胺化; Z是由-C 3BOND C - , - CH = CH-表示的基团,n是0至10的整数; m是0至3的整数; k 是0〜5的整数,但m为2或3的情况下,Z和k可以在括号内的重复单元内任意变化)为新型化合物,具有促进多不饱和脂肪酸代谢改善的作用,特别是生产 脂质过氧化物的抑制活性(抗氧化活性),血栓素A2受体拮抗作用或产生抑制作用 哺乳动物中5-脂氧合酶代谢物的活性,以及​​用作药物,如抗哮喘药,抗过敏药和脑循环代谢改善剂。

    Coumaran derivatives and their pharmaceutical use
    6.
    发明授权
    Coumaran derivatives and their pharmaceutical use 失效
    香豆素衍生物及其药物用途

    公开(公告)号:US4857516A

    公开(公告)日:1989-08-15

    申请号:US136273

    申请日:1987-12-22

    Abstract: A compound of the formula ##STR1## wherein R is a lower alkyl group, R.sup.0 is hydrogen or an acyl group, R.sup.1 and R.sup.2 are lower alkyl groups which may optionally be substituted or wherein R.sup.1 and R.sup.2 are combined to form a butadienylene group which may optionally be substituted, R.sup.3 and R.sup.4 are hydrogen or alkyl groups which may optionally be substituted or wherein R.sup.3 and R.sup.4 are combined to form a polymethylene group, and R.sup.5 is a lower alkyl, aromatic or heterocyclic group which may optionally be substituted or a pharmaceutically acceptable salt thereof, exerts cardiovascular system improving action and antiallergic action and can be used as pharmaceutics, e.g. antithromotics, antiallergic agents etc.

    Abstract translation: 式(I)的化合物,其中R是低级烷基,R 0是氢或酰基,R 1和R 2是可任意被取代的低级烷基,或其中R 1和R 2结合形成丁二烯基 可以任选被取代的基团,R 3和R 4是氢或可以任选被取代的烷基,或者其中R 3和R 4结合形成多亚甲基,R 5是可任意被取代的低级烷基,芳族或杂环基, 其药学上可接受的盐发挥心血管系统改善作用和抗过敏作用,可用作药物,例如, 抗血栓药,抗过敏剂等

    5-pyridyl-1,3-thiazole derivatives
    7.
    发明授权
    5-pyridyl-1,3-thiazole derivatives 失效
    5-吡啶基-1,3-噻唑衍生物

    公开(公告)号:US4612321A

    公开(公告)日:1986-09-16

    申请号:US647436

    申请日:1984-09-05

    CPC classification number: C07D417/04 C07D417/14

    Abstract: Novel compounds of the formula: ##STR1## wherein R.sup.1 stands for an optionally substituted alkyl group, alkenyl group, aryl group, aralkyl group, cycloalkyl group, heterocyclic group having carbon as the bonding hand or amino group, R.sup.2 stands for a pyridyl group which may be substituted with alkyl group, and R.sup.3 stands for an optionally substituted aryl group or salts thereof, have analgesic, anti-piretic, anti-inflammatory and anti-ulcer actions, and can be administered to mammals for the therapy of pain, inflammatory diseases, rheumatic chronic diseases.

    Abstract translation: 下式的新型化合物:其中R1代表任选取代的烷基,烯基,芳基,芳烷基,环烷基,具有碳作为键合或氨基的杂环基,R2代表 可以被烷基取代的吡啶基,R3代表任意取代的芳基或其盐具有止痛,抗皮质,抗炎和抗溃疡作用,并且可以施用于哺乳动物治疗疼痛 ,炎性疾病,风湿性慢性疾病。

Patent Agency Ranking